Chimeric Therapeutics is trading at A$0.01 (-27.27%) following unexplained selling during the September 4 session; no verified company-specific announcement directly explains the move.
- The September 4 filing concerned an application to quote 14,814,814 new shares, which may have increased supply, but no source explicitly links it to the decline.
- The earlier clinical-trial halt remains negative background, not a confirmed September 7 catalyst.